论文部分内容阅读
目的观察甘精胰岛素(长秀霖)治疗2型糖尿病的临床疗效及其安全性。方法对547例2型糖尿病患者血糖不达标者进行治疗观察。入组后予以甘精胰岛素(长秀霖)或甘精胰岛素加口服降糖药物或甘精胰岛素加速效胰岛素皮下注射进行血糖调节,比较不同治疗方案的血糖控制情况,并记录住院期间及出院后随访一周的低血糖发生情况。结果经甘精胰岛素(长秀霖)或甘精胰岛素加口服降糖药物或甘精胰岛素加速效胰岛素皮下注射治疗后患者空腹血糖、餐后2h血糖明显下降(P<0.05)。其中20例(32次)发生轻度低血糖,经基础胰岛素或餐前胰岛素剂量调整后症状消失。最终治疗方案一针甘精胰岛素、一针甘精胰岛素加一种口服降糖药、一针甘精胰岛素加速效胰岛素及一针甘精胰岛素加多种口服降糖药所占比例分别为8.0%、36.0%、17.9%、38.1%。甘精胰岛素和二甲双胍合用,可更好的控制餐后血糖,且低血糖的发生无总体无差异。结论甘精胰岛素对2型糖尿病降糖效果明显,且安全性高。
Objective To observe the clinical efficacy and safety of insulin glargine (Changxiu lin) in the treatment of type 2 diabetes mellitus. Methods A total of 547 type 2 diabetic patients with non-compliance were observed. Into the group after glargine (Changxiu Lin) or insulin glargine plus oral hypoglycemic agents or insulin glargine insulin accelerated insulin subcutaneous injection of blood glucose control, blood glucose control different treatment options, and record during hospitalization and after discharge One week’s follow-up of hypoglycemia. Results Fasting plasma glucose was observed after insulin glargine (Changxiu Lin) or insulin glargine plus oral hypoglycemic agents or insulin glargine at subcutaneous injection for 2 hours. The blood glucose decreased significantly 2h after meal (P <0.05). Mild hypoglycemia occurred in 20 patients (32 times) and disappeared after basal insulin or preprandial insulin dose adjustment. The final treatment of a needle glargine, an injection of insulin glargine plus an oral hypoglycemic agents, an injection of insulin glargine insulin and a needle of insulin glargine plus a variety of oral hypoglycemic agents were 8.0% , 36.0%, 17.9%, 38.1%. Glargine and metformin combined, can better control the postprandial blood glucose, and the incidence of hypoglycemia no overall no difference. Conclusion Glargine has a significant hypoglycemic effect on type 2 diabetes and is safe.